ALX Oncology (ALXO) vs Journey Medical (DERM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Journey Medical (DERM) has outperformed ALX Oncology (ALXO) over the past year, losing 20.9% versus a loss of 40.1%. Journey Medical is the larger company by market cap ($178.1 million vs $172.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | DERM |
|---|---|---|
| Share price | $1.25 | $6.31 |
| Market cap | $172.85M | $178.10M |
| 1-day change | +5.93% | +6.05% |
| YTD return | +4.42% | -22.83% |
| 1-year return | -40.10% | -20.88% |
| 5-year return | -98.00% | — |
| EPS (TTM) | $-1.13 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $9.56 |
| 52-week low | $1.05 | $4.31 |
| Distance from 52-week high | -53.01% | -33.96% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +268.00% | +117.91% |
| Average volume | 1.04M | 184.01K |
| Shares outstanding | 138.28M | 22.22M |
| Employees | 48 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DERM has outperformed ALXO by 19.2 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
ALXO vs DERM FAQ
Which is bigger, ALX Oncology or Journey Medical?
Journey Medical (DERM) is larger, with a market capitalization of $178.10M compared with $172.85M for ALX Oncology (ALXO).
Which stock has performed better over the past year, ALXO or DERM?
DERM returned -20.88% over the past 12 months, compared with -40.10% for ALXO (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Journey Medical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.